Results 1 to 10 of about 158,439 (143)

Plasmodium falciparum

open access: yesTrends in Parasitology, 2019
Plasmodium falciparum is the etiological agent of malaria tropica, the leading cause of death due to a vector-borne infectious disease, claiming 0.5 million lives every year. The single-cell eukaryote undergoes a complex life cycle and is an obligate intracellular parasite of hepatocytes (clinically silent) and erythrocytes (disease causing).
Maier, Alex   +3 more
openaire   +5 more sources

Malaria in children of Tshimbulu (Western Kasai, Democratic Republic of the Congo): epidemiological data and accuracy of diagnostic assays applied in a limited resource setting [PDF]

open access: yes, 2016
BACKGROUND: The literature data on malaria in Western Kasai, DRC, are limited and inadequate. A recent molecular survey there has detected Plasmodium ovale and Plasmodium malariae as mixed infections with Plasmodium falciparum.
Bellina, Livia   +6 more
core   +2 more sources

Recent advances in malaria genomics and epigenomics [PDF]

open access: yes, 2016
Malaria continues to impose a significant disease burden on low- and middle-income countries in the tropics. However, revolutionary progress over the last 3 years in nucleic acid sequencing, reverse genetics, and post-genome analyses has generated step ...
Kirchner, Sebastian   +2 more
core   +1 more source

Plasmodium falciparum [PDF]

open access: yesEmerging Topics in Life Sciences, 2017
Plasmodium falciparum is a protozoan parasite that causes the most severe form of human malaria. Five other Plasmodium species can also infect humans — P. vivax, P. malariae, P. ovale curtisi, P. ovale wallikeri and P. knowlesi — but P. falciparum is the most prevalent Plasmodium species in the African region, where 90% of all malaria occurs, and it is
openaire   +2 more sources

Prospective evaluation of artemether-lumefantrine for the treatment of non-falciparum and mixed-species malaria in Gabon [PDF]

open access: yes, 2012
Background: The recommendation of artemisinin combination therapy (ACT) as first-line treatment for uncomplicated falciparum malaria is supported by a plethora of high quality clinical trials.
Adegnika, Ayola A.   +12 more
core   +1 more source

PNAS plus: plasmodium falciparum responds to amino acid starvation by entering into a hibernatory state [PDF]

open access: yes, 2012
The human malaria parasite Plasmodium falciparum is auxotrophic for most amino acids. Its amino acid needs are met largely through the degradation of host erythrocyte hemoglobin; however the parasite must acquire isoleucine exogenously, because this ...
Baertl   +46 more
core   +1 more source

Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. [PDF]

open access: yes, 2009
BACKGROUND: Although the molecular basis of resistance to a number of common antimalarial drugs is well known, a geographic description of the emergence and dispersal of resistance mutations across Africa has not been attempted.
A-Elbasit, Ishraga E   +40 more
core   +4 more sources

Robust, reproducible, industrialized, standard membrane feeding assay for assessing the transmission blocking activity of vaccines and drugs against Plasmodium falciparum. [PDF]

open access: yes, 2015
BackgroundA vaccine that interrupts malaria transmission (VIMT) would be a valuable tool for malaria control and elimination. One VIMT approach is to identify sexual erythrocytic and mosquito stage antigens of the malaria parasite that induce immune ...
Abebe, Yonas   +9 more
core   +1 more source

Nascent RNA sequencing reveals mechanisms of gene regulation in the human malaria parasite Plasmodium falciparum. [PDF]

open access: yes, 2017
Gene expression in Plasmodium falciparum is tightly regulated to ensure successful propagation of the parasite throughout its complex life cycle. The earliest transcriptomics studies in P.
Batugedara, Gayani   +5 more
core   +1 more source

Lead optimisation of dehydroemetine for repositioned use in malaria [PDF]

open access: yes, 2020
Drug repositioning offers an effective alternative to de novo drug design to tackle the urgent need for novel anti-malarial treatments. The anti-amoebic compound, emetine dihydrochloride, has been identified as a potent in-vitro inhibitor of the multi ...
Abubaker, M   +8 more
core   +3 more sources

Home - About - Disclaimer - Privacy